Stull said that a number of prescription treatments exist for topical psoriasis, such as steroids and injectable therapies, ...

The efficacy and safety of a proposed biosimilar and ustekinumab are similar among adults with moderate to severe plaque psoriasis.

The use of risankizumab after poor response to 2 interleukin-17 inhibitors, secukinumab, and ixekizumab, was safe and effective in plaque psoriasis.

Study highlights the efficacy and safety of tildrakizumab in improving physical, psychological, and social aspects of quality ...

psoriasis drugs market is expected to expand significantly, growing from an estimated USD 19.65 billion in 2024 ...

Can a protein involved in delivering Vitamin D to target tissues have an altered serum profile in psoriasis patients with ...

The company had $583.3 million in cash as of September 30th of 2024; Enough cash to fund its operations until the end of 2027 ...

Symptoms include thick areas of discolored skin covered with scales called plaques. Psoriasis is a chronic skin condition that can flare up unexpectedly. Presently, there is no cure for this ...

doi:10.1111/jdv.13891 Imafuku S, Zheng M, Tada Y, et al. Asian consensus on assessment and management of mild to moderate plaque psoriasis with topical therapy. J Dermatol. 2018;45(7):805-811.

Secukinumab delivers sustained efficacy and quality of life improvements in pediatric generalized pustular psoriasis (GPP).

Emkay Global Financial is bullish on Sun Pharma has recommended buy rating on the stock with a target price of Rs 2400 in its ...

Wouldn’t it be great to sail through the rest of winter with soft skin? For the 78 percent of us bothered by itchy or sore ...